Next Article in Journal
Human Papillomavirus Genotype Distribution in Invasive Cervical Cancer in Pakistan
Next Article in Special Issue
Technical Considerations for the Generation of Adoptively Transferred T Cells in Cancer Immunotherapy
Previous Article in Journal
TCF/LEF Transcription Factors: An Update from the Internet Resources
Previous Article in Special Issue
A Perspective of Immunotherapy for Prostate Cancer
Article Menu

Export Article

Open AccessReview
Cancers 2016, 8(8), 71;

CD8 T Cell–Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas

Department of Urology, University of Minnesota, Minneapolis, MN 55455, USA
Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA
Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
Author to whom correspondence should be addressed.
Academic Editor: Vita Golubovskaya
Received: 25 April 2016 / Revised: 30 June 2016 / Accepted: 19 July 2016 / Published: 27 July 2016
(This article belongs to the Special Issue Cancer Immunotherapies)
Full-Text   |   PDF [549 KB, uploaded 27 July 2016]   |  


Malignant brain tumors continue to represent a devastating diagnosis with no real chance for cure. Despite an increasing list of potential salvage therapies, standard-of-care for these patients has not changed in over a decade. Immunotherapy has been seen as an exciting option, with the potential to offer specific and long lasting tumor clearance. The “gold standard” in immunotherapy has been the development of a tumor-specific CD8 T cell response to potentiate tumor clearance and immunological memory. While many advances have been made in the field of immunotherapy, few therapies have seen true success. Many of the same principles used to develop immunotherapy in tumors of the peripheral organs have been applied to brain tumor immunotherapy. The immune-specialized nature of the brain should call into question whether this approach is appropriate. Recent results from our own experiments require a rethinking of current dogma. Perhaps a CD8 T cell response is not sufficient for an organ as immunologically unique as the brain. Examination of previously elucidated principles of the brain’s immune-specialized status and known immunological preferences should generate discussion and experimentation to address the failure of current therapies. View Full-Text
Keywords: brain tumors; immunotherapy; T cells brain tumors; immunotherapy; T cells

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Murphy, K.A.; Griffith, T.S. CD8 T Cell–Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas. Cancers 2016, 8, 71.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top